Child-Turcotte-Pugh

The Child-Turcotte-Pugh (CTP) score is a clinical scoring system that assesses the prognosis and severity of chronic liver disease, particularly cirrhosis, using five parameters: total bilirubin, serum albumin, prothrombin time (expressed as INR), and the clinical assessments of ascites and hepatic encephalopathy. Each parameter receives 1-3 points, yielding a total score of 5-15 points. The score stratifies patients into three classes with dramatically different outcomes: Class A (5-6 points) indicates well-compensated liver disease with 1-year survival of 100% and 2-year survival of 85-90%, representing patients who typically have normal or mildly abnormal lab values and no ascites or encephalopathy. Class B (7-9 points) represents moderate hepatic dysfunction with 1-year survival of 81% and 2-year survival of 60%, characterizing patients with clinically significant but manageable complications. Class C (10-15 points) indicates advanced decompensated cirrhosis with 1-year survival of only 45% and 2-year survival of 35%, representing patients with severe laboratory abnormalities and clinical decompensation. For surgical risk stratification, Class A patients have operative mortality of 10%, Class B 30%, and Class C 76-82%, making CTP score essential for pre-operative risk assessment. The score was originally developed in 1964 (Child-Turcotte) and modified in 1973 (Pugh) to predict outcomes after portosystemic shunt surgery, but now guides decisions regarding liver transplantation, surgical candidacy, cancer treatments, and overall prognosis.

The CTP score uses specific numerical thresholds for each parameter: Total bilirubin receives 1 point if <2 mg/dL (34 μmol/L), 2 points if 2-3 mg/dL (34-50 μmol/L), and 3 points if >3 mg/dL (>50 μmol/L). For patients with primary biliary cholangitis or primary sclerosing cholangitis, modified cutoffs are used: 1 point (<4 mg/dL), 2 points (4-10 mg/dL), 3 points (>10 mg/dL) because these cholestatic conditions cause markedly elevated bilirubin independent of synthetic function. Serum albumin scores 1 point if >3.5 g/dL, 2 points if 2.8-3.5 g/dL, and 3 points if <2.8 g/dL, reflecting hepatic synthetic function—normal albumin is 3.5-5.5 g/dL. INR (International Normalized Ratio) receives 1 point if <1.7, 2 points if 1.7-2.3, and 3 points if >2.3, measuring coagulation factor synthesis—normal INR is 0.8-1.2. Some centers use prothrombin time instead: 1 point (<4 seconds prolonged), 2 points (4-6 seconds), 3 points (>6 seconds). Ascites is clinically graded: 1 point for none (absent on physical exam and imaging), 2 points for slight/mild (detectable on ultrasound but not physical exam, or easily controlled with diuretics), 3 points for moderate to severe (clinically obvious on exam, tense ascites, or refractory to diuretics). Hepatic encephalopathy scores: 1 point for none (grade 0), 2 points for grade 1-2 (mild confusion, asterixis, altered sleep), 3 points for grade 3-4 (severe confusion, somnolence, or coma). For example, a patient with bilirubin 1.8 mg/dL (1 point), albumin 3.2 g/dL (2 points), INR 1.5 (1 point), no ascites (1 point), and no encephalopathy (1 point) totals 6 points = Class A.

The CTP score is applied across diverse etiologies of chronic liver disease, though prognosis varies by underlying cause even within the same CTP class. Alcohol-related liver disease is the most common indication in Western countries, accounting for 30-40% of cirrhosis cases. These patients can show dramatic improvement with abstinence—a Class B or even early Class C patient may improve to Class A within 3-6 months of complete alcohol cessation, with bilirubin dropping from 3.5 to 1.2 mg/dL and albumin rising from 2.6 to 3.8 g/dL. However, continued drinking with Class C cirrhosis carries 1-year mortality exceeding 60%. Chronic hepatitis C (25-30% of cirrhosis) historically showed progressive deterioration, but direct-acting antivirals now cure 95%+ of infections, potentially improving CTP scores over time—sustained virologic response can improve a Class B patient to Class A within 1-2 years. Non-alcoholic fatty liver disease (NAFLD) is increasingly prevalent (20-25% of cirrhosis), associated with obesity, diabetes, and metabolic syndrome. Weight loss of 10% body weight can improve CTP parameters modestly. Hepatitis B (10-15% in endemic areas) is managed with antiviral therapy (tenofovir, entecavir), which can prevent progression and occasionally reverse early cirrhosis. Primary biliary cholangitis and primary sclerosing cholangitis (5-8% combined) have cholestatic patterns requiring modified bilirubin scoring. Autoimmune hepatitis (5%) may respond dramatically to immunosuppression. Hemochromatosis, Wilson's disease, and alpha-1 antitrypsin deficiency comprise 3-5% and require disease-specific therapies. Regardless of etiology, hepatocellular carcinoma develops in 1-4% of cirrhotic patients annually, with median survival in Class C patients with HCC being only 3-6 months versus 1-2 years in Class A. CTP scoring remains valid across etiologies but treatment of underlying disease significantly modifies the natural history.

CTP scoring plays a critical role in surgical decision-making, though it has been partially supplanted by MELD (Model for End-Stage Liver Disease) score for transplant allocation. For liver transplantation candidacy, CTP Class B and C patients are generally considered, as they have significant mortality risk without transplant. However, MELD score (using bilirubin, INR, and creatinine) is now the primary allocation system in most countries because it better predicts 3-month mortality—MELD ≥15 (roughly correlating with CTP Class B/C) typically qualifies for listing. A patient with CTP score 10 (Class C) usually has MELD 18-25, indicating 1-year mortality of 40-60% without transplant. For non-transplant abdominal surgery, CTP score predicts operative mortality precisely: Class A patients undergoing elective abdominal surgery have perioperative mortality of 10%, making surgery relatively safe for necessary procedures like cholecystectomy or hernia repair. Class B patients have perioperative mortality of 30%, requiring careful risk-benefit analysis—surgery should be postponed if possible or reserved for truly necessary interventions. Class C patients have prohibitive operative mortality of 76-82%, making elective surgery essentially contraindicated; even emergency procedures carry mortality exceeding 50%. For hepatic resection for hepatocellular carcinoma, CTP score determines candidacy: Class A patients tolerate major hepatectomy (removing 3+ segments) with mortality <5%; Class B patients may tolerate limited resection (1-2 segments) with mortality 10-20%; Class C patients are not surgical candidates and require alternative treatments (transplantation, ablation, chemoembolization). For portosystemic shunt procedures (the original CTP indication), Class A/B patients benefit from shunts for refractory variceal bleeding, while Class C patients have 30-day mortality exceeding 50% and should be considered for urgent transplantation instead. The score also guides cancer therapy intensity—Class A cirrhotic patients may receive full-dose chemotherapy, while Class B/C require dose reduction or supportive care only.

Despite widespread use, the CTP score has significant limitations that have led to development of alternative systems. Subjectivity is a major issue—ascites and encephalopathy grading are observer-dependent, with inter-rater reliability only 70-80%, meaning two clinicians may assign different scores to the same patient. A patient with minimal confusion might score 1 point (none) from one evaluator and 2 points (grade 1-2) from another, changing the classification from Class A to Class B. Ceiling effect limits discrimination among sicker patients—multiple Class C patients scoring 12-15 points have vastly different prognoses, but CTP doesn't distinguish them. Non-linear relationship between score and mortality exists—the difference between 5 and 6 points (both Class A) is minimal, while 9 versus 10 points (Class B versus C boundary) is dramatic. Renal function is not incorporated despite being a powerful mortality predictor—CTP fails to distinguish a patient with normal creatinine from one with hepatorenal syndrome. MELD score addresses several limitations using objective laboratory values: MELD = 3.78×ln(bilirubin mg/dL) + 11.2×ln(INR) + 9.57×ln(creatinine mg/dL) + 6.43. MELD ranges 6-40+, with each point increase representing 1-2% increased 3-month mortality. MELD is superior for predicting short-term mortality and is the standard for transplant allocation in the U.S. and Europe. For example, MELD 20 corresponds to 6% 3-month mortality, MELD 30 to 30%, and MELD 40 to 71%. MELD-Na adds sodium to further refine predictions. For hepatocellular carcinoma specifically, the Barcelona Clinic Liver Cancer (BCLC) staging system combines CTP class with tumor characteristics and performance status to guide treatment. For primary biliary cholangitis, the Mayo Risk Score and UK-PBC score better predict outcomes than CTP. Despite these alternatives, CTP remains valuable for its simplicity, applicability across liver disease etiologies, and extensive validation over 50+ years—many centers use both CTP and MELD complementarily for comprehensive assessment.

The frequency of CTP reassessment depends on disease stability and clinical context. For stable Class A cirrhotic patients, reassessment every 6-12 months is appropriate, checking for progression to Class B which would alter surveillance intensity and treatment discussions. For Class B patients, reassessment every 3-6 months monitors for improvement (with treatment) or deterioration to Class C. For Class C patients, monthly or even bi-weekly assessment may be warranted, as these patients are transplant candidates requiring current MELD/CTP scores for listing updates. After specific interventions, reassessment timing varies: following alcohol cessation, recheck at 1 month and 3 months to capture improvement—albumin typically takes 3-6 weeks to rise, bilirubin may decrease within 2-4 weeks, and ascites may resolve in 4-8 weeks with diuretics. After hepatitis C cure, reassess at 6 and 12 months post-treatment, as improvements are gradual. Following decompensation events (variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome), reassess 2-4 weeks after stabilization to determine new baseline. Clinically significant changes indicating progression include: bilirubin increasing from <2 to >3 mg/dL (Class A to potential Class B/C), albumin dropping from >3.5 to <2.8 g/dL (2-point swing), development of new ascites (1-2 point increase), or onset of encephalopathy (1-2 point increase). A 2-point increase within 3-6 months signals rapid deterioration—for example, going from 6 points (Class A) to 8 points (Class B) might represent bilirubin rising and new mild ascites, indicating disease acceleration and prompting transplant evaluation. Conversely, improvement by 2+ points with treatment (e.g., 9 points to 7 points after abstinence and diuretic management) represents meaningful clinical response. A patient transitioning from Class B to Class C (10+ points) has crossed a critical threshold with 1-year survival dropping from 81% to 45%, making this a pivotal change requiring urgent transplant evaluation, palliative care discussions, and intensification of medical management.